{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lacrimal+Apparatus+Diseases",
    "query": {
      "condition": "Lacrimal Apparatus Diseases"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 623,
    "total_pages": 63,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lacrimal+Apparatus+Diseases&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T04:24:10.198Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03452397",
      "title": "Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)",
          "type": "DRUG"
        },
        {
          "name": "1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)",
          "type": "DRUG"
        },
        {
          "name": "2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2018-02-27",
      "completion_date": "2018-04-27",
      "has_results": true,
      "last_update_posted_date": "2021-12-14",
      "last_synced_at": "2026-06-11T04:24:10.198Z",
      "location_count": 3,
      "location_summary": "Louisville, Kentucky • Andover, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452397"
    },
    {
      "nct_id": "NCT03636061",
      "title": "Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline) nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2018-08-15",
      "completion_date": "2018-09-26",
      "has_results": true,
      "last_update_posted_date": "2021-10-25",
      "last_synced_at": "2026-06-11T04:24:10.198Z",
      "location_count": 3,
      "location_summary": "Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03636061"
    },
    {
      "nct_id": "NCT00406510",
      "title": "Comparison of Frequency of Use of Optive and Systane",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Optive, Systane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innovative Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-06-01",
      "last_synced_at": "2026-06-11T04:24:10.198Z",
      "location_count": 1,
      "location_summary": "Azusa, California",
      "locations": [
        {
          "city": "Azusa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00406510"
    },
    {
      "nct_id": "NCT02780674",
      "title": "A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc"
      ],
      "interventions": [
        {
          "name": "MEDI7734",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2016-08-26",
      "completion_date": "2017-11-27",
      "has_results": false,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-06-11T04:24:10.198Z",
      "location_count": 7,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Danbury, Connecticut + 4 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "DeBary",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02780674"
    },
    {
      "nct_id": "NCT02526290",
      "title": "Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dry Eye Syndromes",
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "Intranasal Lacrimal Neurostimulator (Oculeve)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Oculeve, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2015-08-31",
      "completion_date": "2016-04-30",
      "has_results": true,
      "last_update_posted_date": "2017-10-31",
      "last_synced_at": "2026-06-11T04:24:10.198Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02526290"
    },
    {
      "nct_id": "NCT06176651",
      "title": "Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye",
        "Dry Eye, Evaporative",
        "Dry Eye Disease",
        "Evaporative Dry Eye",
        "Evaporative Dry Eye Disease",
        "Kerato Conjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "Miebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gordon Schanzlin New Vision",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2023-09-21",
      "completion_date": "2024-04-05",
      "has_results": false,
      "last_update_posted_date": "2024-04-09",
      "last_synced_at": "2026-06-11T04:24:10.198Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06176651"
    },
    {
      "nct_id": "NCT03706443",
      "title": "Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dry Eye Syndromes",
        "Keratoconjunctivitis Sicca",
        "Lacrimal Apparatus Diseases",
        "Keratoconjunctivitis",
        "Eye Diseases",
        "Keratitis",
        "Corneal Disease",
        "Ophthalmic Solution"
      ],
      "interventions": [
        {
          "name": "Systane Complete",
          "type": "OTHER"
        },
        {
          "name": "Systane Ultra",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2018-12-05",
      "completion_date": "2019-02-28",
      "has_results": false,
      "last_update_posted_date": "2019-05-23",
      "last_synced_at": "2026-06-11T04:24:10.198Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03706443"
    },
    {
      "nct_id": "NCT01561040",
      "title": "Oral Nutrition Impact on Tear Film",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye Syndrome"
      ],
      "interventions": [
        {
          "name": "Omega 3, Vitamins A, D3 and E",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Eye and Vision Technologies and Research Institute",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 80,
      "start_date": "2012-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2012-03-26",
      "last_synced_at": "2026-06-11T04:24:10.198Z",
      "location_count": 4,
      "location_summary": "Conifer, Colorado • Oak Lawn, Illinois • Lexington, Kentucky + 1 more",
      "locations": [
        {
          "city": "Conifer",
          "state": "Colorado"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Creve Coeur",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561040"
    },
    {
      "nct_id": "NCT01250171",
      "title": "The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Secukinumab 10 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Canakinumab 10 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 72,
      "start_date": "2010-11",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2013-01-07",
      "last_synced_at": "2026-06-11T04:24:10.198Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01250171"
    },
    {
      "nct_id": "NCT02240615",
      "title": "The Sinopsys Lacrimal Stent for Lacrimal System Repair in Epiphora",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Epiphora"
      ],
      "interventions": [
        {
          "name": "Sinopsys Lacrimal Stent",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Sinopsys Surgical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2014-10",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-02-12",
      "last_synced_at": "2026-06-11T04:24:10.198Z",
      "location_count": 4,
      "location_summary": "Stanford, California • Aurora, Colorado • Sarasota, Florida + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Kingston",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02240615"
    }
  ]
}